ENSC · Ensysce Biosciences Inc
United States · RS rating 39 · As of 2026-11-03
| Price | 0.38 USD |
|---|---|
| 1-day change | -1.1% |
| RS rating (overall / 1M / 3M / 12M) | 39 / 35 / 75 / 8 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 29 / 29 / 41 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +41.9% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +82.4% |
| Market cap (USD) | $3.9M |